All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubLymphoma HubMDS HubMPN Hub

How can MRD assessment help when treating patients with high-risk MM after transplantation?

Apr 11, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new development in the diagnosis and monitoring of multiple myeloma.

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Elena Zamagni, University of Bologna, Bologna, IT. We asked, How can MRD assessment help when treating patients with high-risk MM after transplantation?

How can MRD assessment help when treating patients with high-risk MM after transplantation?

In this video, Zamagni discusses how high-risk patients are treated the same as low/medium-risk patients, and can achieve a good response. Zamagni then talks about recent trials, including the MASTER trial, which highlights the difficulties faced by high-risk patients in maintaining MRD negativity. Finally, Zamagni discusses how consolidation therapy and better MRD monitoring could benefit high-risk patients.

 

Share: